The Food and Drug Administration is holding a public workshop regarding scientific and clinical trial design considerations for development of new tuberculosis drug regimens. This public workshop is intended to provide information for and gain perspective pertaining to development efforts around new in vitro and in vivo models, new biomarkers and tuberculosis diagnostics, assessing the contribution of 2 or more new components used in combination for to a tuberculosis regimen and clinical trial design challenges.